Redwood AI and Resilience Biosciences Forge a Patent-Savvy Path to Non-Opioid Therapies

Redwood AI's collaboration embeds patent analysis into early drug discovery, targeting non-opioid treatments for withdrawal and pain with its Reactosphere platform.

When most AI drug-discovery firms strike a pharma deal, they trade on speed — faster molecule hunting, quicker hit identification. Redwood AI is taking a different tack. Its new collaboration with Vancouver-based Resilience Biosciences builds intellectual property assessment directly into the early-stage chemistry workflow, aiming to cut the time between a promising scaffold and a protectable compound.

The partnership zeroes in on non-opioid therapeutics for opioid withdrawal, withdrawal pain, and related neurocognitive symptoms — an area where the need for novel, non-addictive treatments is urgent. Resilience Biosciences, a clinical biopharma company, will tap Redwood's Reactosphere platform to systematically explore chemical structure space, plan synthetic routes via retrosynthesis, and evaluate patentability and freedom-to-operate in parallel. The goal: deploy lab resources only after AI has filtered candidates with both biological promise and clear IP positioning.

"We are building a next-generation integrated translational platform for addiction, pain, and neuropsychiatric disorders," said Matthew Roberts, Chief Operations Advisor at Resilience. "This collaboration fits our long-term strategy of combining cutting-edge AI with rigorous drug development." Prof. Anthony Phillips, Resilience's CEO, underlined that AI-driven workflows align with the company's platform approach.

Redwood CEO Louis Dron described the deal as a natural application of the company's technology in the life sciences. The collaboration will also produce a synthetic assistance workflow co-developed by both teams to help modify drug scaffolds and open up new chemical territories.

The pact arrives on the heels of a busy stretch for Redwood. On May 14, 2026, the company rolled out a new optimization module for Reactosphere designed to help chemists improve experiments while saving time and materials. A research tie-up with the University of British Columbia meanwhile expanded the platform's training universe to over 21 million reaction examples. Reactosphere now runs in a production-grade cloud environment — a prerequisite for scaling outside the lab.

Separately, Redwood AI Operations received a grant of up to 240,000 Canadian dollars from the National Research Council of Canada for the Q-SAFE project, an initiative that uses AI and quantum-optimised methods to improve risk classification of hazardous chemicals. That funding adds a layer of government validation to Redwood's technology stack, alongside its recent inclusion on Innovate BC's list of the 25 most investable companies in the province.

Earlier this year, Redwood explored applications in the defence and security sector, supported by consulting services from the National Research Council. The Resilience partnership marks a return to pharma as a core focus, though the company continues to keep a foot in multiple verticals.

By weaving patent analysis into the core chemistry workflow, Redwood is betting that the most valuable drug candidates are not just potent — they are legally defensible from day one. It is a bet that could set the collaboration apart from a crowded field of AI-pharma tie-ups, provided the platform delivers on its technical promises.